



**Terumo Report  
2021**

## Group Mission

### Contributing to Society through Healthcare

We contribute to society by providing valued products and services in the healthcare market and by responding to the needs of patients and healthcare professionals.

## Core Values

### Respect — Appreciative of others

We show respect and appreciation toward associates, customers, and business partners.

We value individuality and diverse cultures, and listen widely and carefully to different opinions and the voice of society.

### Integrity — Guided by our mission

As associates of Terumo Group, responsible for life and health, we always act with sincerity and a sense of mission.

Through our daily efforts, we build trust among all stakeholders.

### Care — Empathetic to patients

We are mindful that everything we do ultimately connects us to patients.

We strive to understand healthcare providers deeply and work together with them to give patients a better future.

### Quality — Committed to excellence

To ensure safety and reliability in healthcare, we view each issue from a “gemba” perspective in order to find the optimal solution.

As well as product quality, we pursue excellence in all we do, from product supply to customer care.

### Creativity — Striving for innovation

We promote a mindset that embraces challenge for the future, and work with curiosity and passion.

We respond to the needs of “gemba” by delivering products and services that create meaningful value in a timely manner.



## In 2021, Terumo marked its 100th anniversary.

100 years have passed since Terumo's foundation.

Its debut product, the domestically produced safe, high-quality thermometer, was launched on the market in the hope of delivering it to as many people as possible.

Under the Group Mission: Contributing to Society through Healthcare, we have since continually supported the medical arena worldwide with our innovative developments and quality, while working side by side with medical professionals active at the most critical point of human life.

Now, 100 years later, by coincidence, the world is facing once again a new and major challenge.

With our mission in mind, Terumo will, without resting on its laurels, continue to challenge the limits of medicine for further improvement of the medical care of tomorrow, through our passionate commitment for another 100 years.

“Stride Ahead” encompasses our belief that big steps forward will lead to a better future for medicine.

We are Terumo.

100th Anniversary and History of Value Creation

	Group Mission / Core Values
4	Message from the President and CEO
10	100 Years of Terumo —History of Value Creation—

Strategy

16	Message from the CAFO
18	Financial and Non-financial Highlights
20	At a Glance
22	Strategies by Company
22	Cardiac and Vascular Company
26	General Hospital Company
30	Blood and Cell Technologies Company
34	R&D and Intellectual Property
39	Digital Transformation (DX)

Foundation Supporting Value Creation

40	Sustainability
42	Human Resource Strategy
44	Environment
48	Corporate Governance
48	Dialogue between Independent Directors
52	Directors, Audit and Supervisory Committee Members, and Executive Officers
65	Risk Management System


Data Section

70	Ten-Year Financial Summary
72	Financial Review
74	Consolidated Financial Statements
80	Corporate Information

Editorial Policy

Terumo prepares communication tools to provide stakeholders with straightforward reporting on the business activities it is pursuing in fulfillment of its Group mission—"Contributing to Society through Healthcare"—and to promote communication with society. Terumo Reports provide brief summaries of financial and non-financial information, including business strengths and key initiatives performance reports, corporate governance structure, and environmental and social efforts, from a mid- to long-term perspective. Sustainability Reports provide wide-ranging information on initiatives that contribute to both the development of a sustainable society and the sustainable growth of the Terumo Group, together with relevant data.

Information Disclosure System



\*1 For fiscal 2020, this report was issued under the name Sustainability Data Book 2020.  
\*2 Scheduled to be issued in December 2021. For fiscal 2020, it was published under the name Shared Value Book 2020.

Coverage

Report coverage includes, in principle, those elements of the global Terumo Group falling within the scope of consolidated earnings statements. When the scope differs from that described above, notification will be provided.

Covered Period

The covered period is fiscal 2020 (April 1, 2020–March 31, 2021), but some activities conducted in and after April 2021 are also included.

Adoption of International Financial Reporting Standards

Beginning with its financial results announcement for fiscal 2017, the Company has adopted International Financial Reporting Standards (IFRS) with the goal of making its financial information more easily comparable to that of companies around the world and to improve management accuracy and strengthen corporate governance through the global application of uniform rules.

Cautionary Statement Regarding Forward-looking Statements

Forward-looking statements in this report, including financial projections, are based upon assumptions using information available at the time and are not intended to be a guarantee of future events or performance. Accordingly, it should be noted that actual results may differ from forecasts and projections due to various factors. Factors affecting actual results include, but are not limited to, changes in the economic conditions surrounding Terumo, fluctuations in foreign exchange rates, and the state of competition. Information on market share in this report is partly derived from our own independent research. Information about products (including products currently in development) included in this report is not intended to constitute advertising or medical advice.

In fiscal 2020, the name of the Blood Management Company was changed to the Blood and Cell Technologies Company. This change is purely a change in name and does not impact segment information. Accordingly, the new name is also used for references pertaining to fiscal 2019 and earlier.